Sanders seeks Ariad data on cancer drug price hikes
(By Ed Silverman for STAT)
Call it Bernie Sanders vs. Ariad Pharmaceuticals, Act Two.
The Vermont senator and erstwhile presidential candidate, who has helped make prescription drug pricing a high-profile issue, sent the company a letter1 on Thursday asking for a plethora of data that might explain a string of “staggering” and “outrageous” price hikes2 for an expensive cancer treatment. Continue reading article here……
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.